# Phase I/II Study of Z-208 in Advanced Hepatocellular Carcinoma (HCC)

> **NCT00731445** · PHASE1,PHASE2 · COMPLETED · sponsor: **Zeria Pharmaceutical** · enrollment: 43 (estimated)

## Conditions studied

- Advanced Hepatocellular Carcinoma

## Interventions

- **DRUG:** Z-208

## Key facts

- **NCT ID:** NCT00731445
- **Lead sponsor:** Zeria Pharmaceutical
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-07
- **Primary completion:** 2012-01
- **Final completion:** 2012-06
- **Target enrollment:** 43 (ESTIMATED)
- **Last updated:** 2012-07-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00731445

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00731445, "Phase I/II Study of Z-208 in Advanced Hepatocellular Carcinoma (HCC)". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00731445. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*